Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
Clinical trial NCT02534935 · COMPLETED
Trial details
- NCT number
- NCT02534935
- Sponsor
- Pfizer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-31
- Primary completion
- 2017-08-21
- Enrollment
- 396
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.